No Data
Sanyuan Biotech (301206.SZ) dividend distribution for the first three quarters of 2024: 2.5 yuan per 10 shares, with the equity registration on January 9.
Sanyuan Biological (301206.SZ) announced the distribution of rights for the first three quarters of 2024, based on the company's current total share capital...
Sanyuan Biotech (301206.SZ): Cumulatively repurchased 0.34% of shares.
On January 2, Gelonghui reported that Sanyuan Biological (301206.SZ) announced that as of December 31, 2024, the company has cumulatively repurchased 695,700 shares through the Share Buyback dedicated Account via centralized bidding, accounting for 0.34% of the company's total share capital, with the highest Fill Price at 27.85 yuan per share and the lowest Fill Price at 23.70 yuan per share, for a total transaction amount of 17,602,570.26 yuan (excluding transaction fees).
Express News | Shandong Sanyuan Biotechnology Says Impact of U.S. Move on Co's Production and Operation Uncertain; Co Will Closely Monitor Any Development
Express News | Shandong Sanyuan Biotechnology Says Co Has Set up Special Work Team in Response to Cargill's Investigation Request to U.S. Over Erythritol Products Imported From China
Sanyuan Biological (301206.SZ): "The project for the annual production of 50,000 tons of erythritol and technology center has been completed and the remaining raised funds will be permanently used to supplement working capital."
On December 16, Gelonghui reported that Sanyuan Bio (301206.SZ) held the fourth meeting of the fifth Board of Directors and the fourth meeting of the fifth Supervisory Board on December 16, 2024, and reviewed and approved the proposal on the completion of some fundraising projects and the permanent supplementation of surplus funds into working capital. It was agreed to conclude the fundraising project for the initial public offering of Stocks "Annual production of 50,000 tons of erythritol and technology center project," and to allocate the surplus raised funds of 352.2712 million yuan (including payables for contract balances, warranty funds, and interest already received or receivable after deducting handling fees.
Sanyuan Biological (301206.SZ): The company currently has no plans to acquire a starch enterprise.
According to Gelonghui on December 6, San Yuan Biology (301206.SZ) stated on the investor interaction platform that the company maintains long-term stable cooperation with multiple starch enterprises within the province, which can fully meet the current production needs. As of now, the company has no plans to acquire starch enterprises. If there are related matters, the company will strictly fulfill its information disclosure obligations according to laws and regulations.
No Data
